Harnessing the power of cTRLs
to unlock the next generation of solid tumor cancer therapies
Powering progress in solid tumor treatments
We are harnessing the power of cTRLs – a rare and potent circulating T cell population found in the blood and naturally equipped to fight cancer – to engineer solid tumor cell therapies.
Solid tumors have yet to benefit from curative cell therapy breakthroughs seen in blood cancers. Emerging treatments like TILs utilize exhausted cells from surgically removed cancer tissue, an invasive and complex process for patients, while TCR-based therapies lack a breadth of tumor-specific targets.
We are developing a first of its kind polyclonal cell therapy to treat solid tumors, which represent 90% of all cancers, without the need to surgically remove tumor tissue.
cTRL-based therapy has the potential to eliminate the challenges of invasive surgery and simplify complexities of solid tumor cell therapy development, manufacturing and administration.
Proprietary platform extracts with ease
From a single blood draw, we can obtain sufficient quantities of rare polyclonal cTRLs against solid tumors.
We have unlocked the ability to efficiently isolate and extract millions of cTRLs using a proprietary cell-sorting platform called IsoQore™ that identifies migratory, tumor-reactive cells in the bloodstream via novel markers.
We are experts in cell therapy discovery and development applying decades of experience to the fundamental challenges that have stymied progress against solid tumors. Meet the team redefining solid tumor cell therapy from the ground up.
Meet our team of cell therapy pioneers
